On September 26, about 100 UNDP representatives visited Farmak JSC. The visit took place within the framework of 2016 Procurement and Supply Management Seminar, a part of the overall UNDP participation in the health sector’ capacity development.
UNDP delegation comprised about 100 participants, including representatives of UNICEF and the Ministry of Health, from 30 countries: Iraq, Moldova, Belarus, Kyrgyzstan, Bolivia, Albania, Chad, Mali, Afghanistan, Angola, Bhutan, Fiji, Iran, Nigeria, Zambia, Zimbabwe, South Sudan, North Sudan, Guinea-Bissau, Tajikistan, Turkmenistan, Uzbekistan, Cuba, Equatorial Guinea, Sao Tome and Principe, Ukraine and others. During the event, guests visited production sites of Farmak, quality control laboratories, and a modern laboratory processing facility with a pilot area where the end-to-end principle of scientific and technological development has been realized, from tubes to pilot series.
Also, Farmak guests had a round table discussion, where Oleg Syarkevych, Business Development Director of JSC Farmak, presented his report. He informed on the main operational vectors of a pharmaceutical enterprise, focusing on the international cooperation. Olga Oleksiichuk, Quality Director, addressed participants with a presentation on “Confirmed quality of Farmak drugs”.
Oleg Syarkevych, Farmak Business Development Director: “Meeting the UNDP delegation has provided an excellent opportunity to present Farmak as a reliable partner for prospective cooperation with international organizations to supply medicinal products in accordance with European standards, exchange information with delegates from nearly 30 countries. We have received positive feedback after visiting manufacturing sites and the laboratory facility.”
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...